NCT00772395

Can Risedronate Prevent Periprosthetic Bone Loss After Total Hip Arthroplasty

Can Risedronate Prevent Periprosthetic Bone Loss After Total Hip Arthroplasty. A Randomized, Double-blind, Placebo-controlled, Parallel-group Study

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 78 (actual)
• Sponsor: Danderyd Hospital · Academic / Other
• Sex: All
• Age: 40 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Can risedronate given once weekly for 6 months prevent periprosthetic bone loss after uncemented total hip arthroplasty?

Detailed description

Periprosthetic bone loss after total hip arthroplasty is the main factor in limiting the longevity of implants used for treatment of osteoarthritis. Bone loss leads to implant destabilization. Bisphosphonates, given for approximately 6 months after THA man prevent this bone loss and lead to longer implant fixation and lower incidence of aseptic prosthesis loosening. We perform a clinical trial with risedronate to investigate if we can influence periprosthetic bone loss around a uncemented femoral stem.

Conditions

• Bone Loss

Interventions

Type	Name	Description
DRUG	Risedronate	35 mg given once weekly start on 2nd postoperative day for 26 weeks (6 months)
DRUG	Placebo	Placebo given once weekly start on 2nd postoperative day for 26 weeks (6 months)

Timeline

• Start date: 2006-04-01
• Primary completion: 2013-02-01
• Completion: 2013-02-01
• First posted: 2008-10-15
• Last updated: 2014-09-19

Locations

1 site across 1 country: Sweden